We present the case of a malignant peripheral nerve sheath tumour (MPNST) that developed on the upper lip of an 86 year old woman. MPNSTs are highly aggressive sarcomas that very rarely occur in the face. We know of no other reported cases of a malignant peripheral nerve sheath tumour arising from the upper lip.
INTRODUCTION
Malignant peripheral nerve sheath tumours (MPNSTs) have an incidence of 1 per 1,000,000 people per year (1) and comprise around 3% of soft-tissue sarcomas (2) . Tumours arise from Schwann cells or perineural cells that ensheath axons and extend along neural tracts. They are aggressive cancers that have high rates of recurrence and a poor prognosis (3 ) . Occurrence in the head and neck region has been shown to be a predictor of adverse outcome. Up to half of all treated tumours will metastasize haematogenously (4). We can identify only two cases (5, 6) in the literature of MPNST affecting the lips, in both instances the lower lips were affected. There were no reported cases of a malignant peripheral nerve sheath tumours originating from the upper lip. Here we report a case of MPNST situated in the midline of the upper lip involving the nasal floor and anterior alveolus.
CASE REPORT
An 86 year old woman presented with a painful lump on her upper lip extending into the dome and floor of the nose. The lesion had apparently enlarged over 4 weeks extending through the lip into the floor of the nose. Investigations included, fine needle aspiration (FNA), CT and MRI. A diagnosis of MPNST was made based on histological examination of an incisional biopsy (Fig. 1 ).
The multidisciplinary team (MDT) decision was to resect the lesion with wide-margins (2cms in 3 dimensions) based on the high reported incidence of both perineural and perivascular spread 6 in this tumour group, thus necessitating a rhinectomy, cheilectomy and anterior alveolectomy. The upper lip was reconstructed using a modified Karapandzic flap (Fig. 2, Fig.  3 ).
Osseointegrated implants were placed in the paranasal bone and remaining alveolus for prosthetic reconstruction of the nose. Operative margins were well clear of tumour on histopathological examination with no perineural or perivascular involvement. The option of adjunctive radiotherapy was offered but turned down by the patient. The patient remains under surveillance following rehabilitation with no evidence of recurrence at 16 months. Immunohistochemistry can cloud diagnosis because of variable immunoreactivity for the definitive neural marker, S-100. This tumour was S-100 + Actin + allowing the diagnosis of MPNST to be confirmed post-resection. Adjuvant radiotherapy is effective at reducing the high local recurrence of MPNSTs but provides no survival benefit. 1 Interestingly radiotherapy is also a risk factor for the disease accounting for 10% of cases. (9) Chemotherapy is understudied and as such is controversial for treating MPNST. It is reserved for aggressive unresectable cases.(10) Overall prognosis for MPNSTs is good with a 43% cause specific mortality at 10 years (4) but many patients suffer local recurrence with a consequent increase in related distant metastases (~90% of patients at post-mortem). Poor prognostic factors for recurrence and overall survival are the degree of cellular differentiation and tumour grade respectively.
